



## BIOATLA TO PRESENT AT 39TH ANNUAL J.P. MORGAN VIRTUAL HEALTHCARE CONFERENCE

January 8, 2021

**SAN DIEGO, CA** - January 8, 2021 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of [Conditionally Active Biologic \(CAB\)](#) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present at the 39<sup>th</sup> Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 2:50 PM Eastern Time.

While the conference on the whole is invitation-only, public listeners can listen to our virtual presentation via this link.

[https://jpmorgan.metameetings.net/events/healthcare21/sessions/35735-bioatla/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare21/sessions/35735-bioatla/webcast?gpu_only=true&kiosk=true)

### About BioAtla, Inc.

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and Beijing, China. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has two programs currently in Phase 1/2 clinical testing in the United States, BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). BioAtla's investigational CAB CTLA-4 antibody, BA3071, is subject of a global co-development and collaboration agreement with BeiGene Ltd. for its development, manufacturing and commercialization. BA3071 is a novel, CTLA-4 inhibitor that is designed to be conditionally activated in the tumor microenvironment in order to reduce systemic toxicity and potentially enable safer combinations with checkpoint inhibitors such as BeiGene's anti-PD-1 antibody, tislelizumab.

Learn more at [www.bioatla.com](http://www.bioatla.com)

Contact:

Richard Waldron

Chief Financial Officer

BioAtla, Inc.

[rwaldron@bioatla.com](mailto:rwaldron@bioatla.com)

858.356.8945